Clinical trials: Coronary Vessel
Coronary Artery Disease
Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease
The DESSOLVE II clinical trial is to assess the safety and performance of the sirolimus-eluting MiStent for the treatment for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete…
- Trial name
- DESSOLVE-II (NCT01294748)
- Testing
- MiStent DES, Endeavor DES
- Where
- 28 sites in Belgium, France and 4 more
- Volunteers
- 184 people
- Sponsor
- Micell Technologies
Coronary Artery Disease, Calcifications Vascular
SOLSTICE Trial in China
This is a small sample size clinical trial in Chinese population to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System to treat de novo, calcified, stenotic, coronary lesions…
- Trial name
- NCT05433376
- Testing
- Shockwave Coronary Intravascular Lithotripsy (IVL) System C2
- Where
- 3 sites in China
- Volunteers
- 20 people
- Sponsor
- Genesis Medtech Corporation
Coronary Artery Disease
First in Man Experience With a Drug Eluting Stent in De Novo Coronary Artery Lesions
A prospective, single-treatment, multi centre clinical trial enrolling 30 patients in 2 centres in Romania, with a clinical and angiographic follow-up at 4 and 9 months to determine the primary endpoint of late lumen loss and…
- Trial name
- BIOFLOW-I (NCT01214148)
- Testing
- ORSIRO - Drug Eluting Coronary Stent
- Where
- 2 sites in Romania
- Volunteers
- 30 people
- Sponsor
- Biotronik AG
Delivery of Health Care
Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia
The purpose of this study is to validate the effectiveness of food supplement Limicol on reducing LDL-cholesterol in moderate hypercholesterolemic volunteers.
- Trial name
- NCT01139398
- Testing
- Limicol (plant extract)
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Lescuyer Laboratory
Coronary Disease, Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study
XIENCE V® India is a prospective, open-label, multi-center, observational, single-arm study to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- XIENCE V India (NCT00631228)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 18 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Abbott Medical Devices
Hypercholesterolemia, Coronary Disease
Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)
This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.
- Trial name
- NCT00092599
- Testing
- MK0653, ezetimibe
- Volunteers
- 410 people
- Sponsor
- Organon and Co
Coronary Artery Disease
Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study
The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of…
- Trial name
- NCT02419521
- Testing
- Resolute Onyx Stent - 2.25 mm - 4.0 mm
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- Medtronic Vascular
Cardiac Decompensation
Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices
This is planned as a feasibility study. The objective is to evaluate a specially designed patient adherence and monitoring software on standard mobile devices in remote monitoring of heart failure patients.
- Trial name
- REMOTE-HF-1 (NCT01430936)
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 51 people
- Sponsor
- Aventyn, Inc.
Coronary Atherosclerosis
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)
The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered…
- Trial name
- NCT00124332
- Testing
- Rimonabant (SR141716)
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 839 people
- Sponsor
- Sanofi
ACS, Acute Coronary Syndrome
Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge
The aim of this international study is to describe the short- and long-term (i.e. up to 2 years following the index event) antithrombotic management patterns (AMPs) in patients hospitalized for acute coronary syndromes (ST…
- Conditions
- ACS, Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina
- Trial name
- EPICOR (NCT01171404)
- Where
- 410 sites in Argentina, Belgium and 18 more
- Volunteers
- 10,568 people
- Sponsor
- AstraZeneca
Heart Diseases, Cardiovascular Diseases
Trial Evaluating New Strategy in the Functional Assessment of 3-vessel Disease Using SYNTAXII Score in Patients With PCI
Clinical study that aims to evaluate a new strategy using the SYNTAX II Score calculator in the functional assessment of patients with new coronary 3-vessel-disease who undergo percutaneous coronary intervention (PCI)
- Conditions
- Heart Diseases, Cardiovascular Diseases, 3 Vessel Coronary Artery Disease
- Trial name
- NCT02015832
- Testing
- Coronary stent, Multi Slice Computed Tomography, instantaneous wave-free ratio
- Where
- 22 sites in Netherlands, Poland and 2 more
- Volunteers
- 454 people
- Sponsor
- ECRI bv
Acute Coronary Syndrome
VitalScan MCG Rule-out Multi-centre Pivotal Study - US
A prospective multi-centre observational study to validate the diagnostic accuracy of a transportable magnetocardiograph device for acute coronary syndrome (ACS), focusing on rule-out capability, in patients who present to the…
- Trial name
- MAGNET ACS (NCT03546933)
- Testing
- VitalScan Magnetocardiograph
- Where
- 5 sites in United States
- Volunteers
- 651 people
- Sponsor
- Creavo Medical Technologies Ltd
Atrial Fibrillation
VASC-AF Study: Vascular Closure vs Manual Compression
The aim of this study is to reduce the time to ambulation after PVI by a vascular closure device as compared to manual compression and a figure-of-8 suture only.
- Trial name
- VASC-AF (NCT07414121)
- Testing
- Vacular closure
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Asklepios proresearch
Acute Coronary Syndrome
A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI
An Open-label, Sequential Dose Escalation/De-escalation Clinical Trial of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI.
- Trial name
- NCT06533358
- Testing
- MT1002 Injection
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Coronary Artery Disease, In Stent Restenosis
Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis
This is a prospective, multicenter, randomized controlled clinical trial, which plans to enroll 260 subjects.
- Trial name
- SIBLINT ISR (NCT04240444)
- Testing
- drug-coated balloon Catheter
- Where
- 16 sites in China
- Volunteers
- 260 people
- Sponsor
- B. Braun Medical International Trading Company Ltd.
Acute Coronary Syndrome, Old Myocardial Infarction
Brilinta Clinical Experience Investigation
To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase. 1.
- Trial name
- BRLCEIACS/OMI (NCT03212287)
- Where
- 71 sites in Japan
- Volunteers
- 663 people
- Sponsor
- AstraZeneca
Chronic Stable Angina
Pharmacokinetics of AUX-001 40mg Once-daily in Healthy Subjects Under Fasting and Fed Conditions
Exploratory, single-dose, open-label, pharmacokinetic study to establish uptake, plasma levels safety and tolerability of orally administered AUX-001 on an empty stomach (i.e, fasting) as well as after a meal (i.e.
- Trial name
- NCT06249581
- Testing
- AUX-001 40mg once-daily
- Where
- Portugal
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Auxilius Pharma sp.z.o.o.
Anterior Wall Acute Myocardial Infarction
Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack
The purpose of this study is to evaluate the feasibility of the delivery of SuperSaturated Oxygen (SSO2) Therapy for 60 minutes selectively into the left main coronary artery (LMCA).
- Trial name
- NCT01630707
- Testing
- SuperSaturated Oxygen (SS02) Therapy
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- TherOx
Myocardial Infarction, Heart Failure
Study of Oral PG-116800 Following a Heart Attack
The main purpose of the study is to test whether a possible new drug (called PG-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack.
- Conditions
- Myocardial Infarction, Heart Failure, Heart Enlargement
- Trial name
- NCT00067236
- Testing
- PG-116800 (given as PG-530742)
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 253 people
- Sponsor
- Procter and Gamble
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.